Logo image of GMAB

GENMAB A/S -SP ADR (GMAB) Stock Price, Quote, News and Overview

NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD

22.34  -0.1 (-0.45%)

After market: 22.33 -0.01 (-0.04%)

GMAB Quote, Performance and Key Statistics

GENMAB A/S -SP ADR

NASDAQ:GMAB (2/21/2025, 8:23:59 PM)

After market: 22.33 -0.01 (-0.04%)

22.34

-0.1 (-0.45%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High31.88
52 Week Low18.64
Market Cap14.19B
Shares635.24M
Float609.62M
Yearly DividendN/A
Dividend YieldN/A
PE24.02
Fwd PE15.46
Earnings (Next)05-08 2025-05-08/bmo
IPO10-01 2000-10-01


GMAB short term performance overview.The bars show the price performance of GMAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

GMAB long term performance overview.The bars show the price performance of GMAB in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of GMAB is 22.34 USD. In the past month the price increased by 4.93%. In the past year, price decreased by -23.39%.

GENMAB A/S -SP ADR / GMAB Daily stock chart

GMAB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About GMAB

Company Profile

GMAB logo image Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Company Info

GENMAB A/S -SP ADR

Carl Jacobsens Vej 30

Valby 1560 DK

CEO: Jan G. J. van de Winkel

Employees: 2526

Company Website: https://www.genmab.com/

Investor Relations: https://www.genmab.com/investors

Phone: 4570202728

GENMAB A/S -SP ADR / GMAB FAQ

What is the stock price of GENMAB A/S -SP ADR today?

The current stock price of GMAB is 22.34 USD. The price decreased by -0.45% in the last trading session.


What is the ticker symbol for GENMAB A/S -SP ADR stock?

The exchange symbol of GENMAB A/S -SP ADR is GMAB and it is listed on the Nasdaq exchange.


On which exchange is GMAB stock listed?

GMAB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GENMAB A/S -SP ADR stock?

30 analysts have analysed GMAB and the average price target is 129.74 USD. This implies a price increase of 480.74% is expected in the next year compared to the current price of 22.34. Check the GENMAB A/S -SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENMAB A/S -SP ADR worth?

GENMAB A/S -SP ADR (GMAB) has a market capitalization of 14.19B USD. This makes GMAB a Large Cap stock.


How many employees does GENMAB A/S -SP ADR have?

GENMAB A/S -SP ADR (GMAB) currently has 2526 employees.


What are the support and resistance levels for GENMAB A/S -SP ADR (GMAB) stock?

GENMAB A/S -SP ADR (GMAB) has a resistance level at 22.35. Check the full technical report for a detailed analysis of GMAB support and resistance levels.


Is GENMAB A/S -SP ADR (GMAB) expected to grow?

The Revenue of GENMAB A/S -SP ADR (GMAB) is expected to grow by 17.69% in the next year. Check the estimates tab for more information on the GMAB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENMAB A/S -SP ADR (GMAB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENMAB A/S -SP ADR (GMAB) stock pay dividends?

GMAB does not pay a dividend.


When does GENMAB A/S -SP ADR (GMAB) report earnings?

GENMAB A/S -SP ADR (GMAB) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of GENMAB A/S -SP ADR (GMAB)?

The PE ratio for GENMAB A/S -SP ADR (GMAB) is 24.02. This is based on the reported non-GAAP earnings per share of 0.93 and the current share price of 22.34 USD. Check the full fundamental report for a full analysis of the valuation metrics for GMAB.


What is the Short Interest ratio of GENMAB A/S -SP ADR (GMAB) stock?

The outstanding short interest for GENMAB A/S -SP ADR (GMAB) is 0.27% of its float. Check the ownership tab for more information on the GMAB short interest.


GMAB Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to GMAB. When comparing the yearly performance of all stocks, GMAB is a bad performer in the overall market: 74.67% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GMAB Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to GMAB. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GMAB Financial Highlights

Over the last trailing twelve months GMAB reported a non-GAAP Earnings per Share(EPS) of 0.93. The EPS decreased by -0.37% compared to the year before.


Industry RankSector Rank
PM (TTM) 36.44%
ROA 17.12%
ROE 21.38%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%-57.68%
Sales Q2Q%41.39%
EPS 1Y (TTM)-0.37%
Revenue 1Y (TTM)30.67%

GMAB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to GMAB. The Buy consensus is the average rating of analysts ratings from 30 analysts.

For the next year, analysts expect an EPS growth of 55.36% and a revenue growth 17.69% for GMAB


Ownership
Inst Owners45.28%
Ins OwnersN/A
Short Float %0.27%
Short Ratio1.18
Analysts
Analysts75.33
Price Target129.74 (480.75%)
EPS Next Y55.36%
Revenue Next Year17.69%